JNJ-26146900 | 868691-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: JNJ-26146900
• 英文别名: 2-(2-ethanesulfonyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5-carbonitrile；(-)-2-((R)-2-ethanesulfonyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5-carbonitrile；(-) enantiomer of 2-(2-ethanesulfonyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5-carbonitrile；(-)(R)-2-(2-Ethylsulfonyl-1-hydroxy-1-methylethyl)-6-trifluoromethyl-1H-indole-5-carbonitrile；2-[(2R)-1-ethylsulfonyl-2-hydroxypropan-2-yl]-6-(trifluoromethyl)-1H-indole-5-carbonitrile
• CAS: 868691-50-3
• 化学式: C₁₅H₁₅F₃N₂O₃S
• 分子量: 360.357
• InChiKey: UJGGNFGSHPHGNE-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (-)-2-((R)-2-ethylsulfanyl-1-hydroxy-1-methyl-ethyl)-6-trifluoromethyl-1H-indole-5-carbonitrile 在 Oxone 、 四丁基硫酸氢铵 、 碳酸氢钠 作用下， 以 水 、 乙酸乙酯 为溶剂， 生成 JNJ-26146900
  参考文献：
  名称：

  Novel indole derivatives as selective androgen receptor modulators (SARMS)

  摘要：

  本发明涉及新型吲哚衍生物，含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。

  公开号：

  US20050245485A1

文献信息

• Novel indole derivatives as selective androgen receptor modulators (SARMS)
  申请人：Lanter C. James

  公开号：US20050245485A1

  公开（公告）日：2005-11-03

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物，含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
• Novel indole derivatives as selective androgen receptor modulator (SARMS)
  申请人：Lanter C. James

  公开号：US20050250740A1

  公开（公告）日：2005-11-10

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物，含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
• Indole derivatives as selective androgen receptor modulators (sarms)
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP2078712A1

  公开（公告）日：2009-07-15

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物、含有这些衍生物的药物组合物及其在治疗受雄激素受体调节的紊乱和病症中的用途。
• US7288553B2
  申请人：——

  公开号：US7288553B2

  公开（公告）日：2007-10-30
• β-Alkylthio indolyl carbinols: Potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model
  作者：James C. Lanter、James J. Fiordeliso、Vernon C. Alford、Xuqing Zhang、Kenneth M. Wells、Ronald K. Russell、George F. Allan、Muh-Tsann Lai、Olivia Linton、Scott Lundeen、Zhihua Sui

  DOI：10.1016/j.bmcl.2007.02.014

  日期：2007.5

  Through an in vivo screening model, we developed the in vivo SAR of [beta-alkylthio indolyl carbinols. Through these efforts we identified a compound with potent oral in vivo efficacy in both immature and mature rat prostate weight reduction models and in a murine xenograft prostate cancer model. (c) 2007 Elsevier Ltd. All rights reserved.